Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Same Issues, New Issues
Barclays indicated the weakness was centered on its high throughput sequencing line of instruments, which has been weak in the three quarters of 2016.
However, the firm noted that some new weak areas have also emerged, as the company cribbed on weakness in Americas, adding on to its first half commentary of European weakness. Additionally, the firm pointed to the below-norm HiSeq utilization, which was below $300,000 per instrument.
Poised For Slowest Growth In Over 4 Years?
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Analyst Jack Meehan expects fourth-quarter revenues to be up 3.7 percent year-over-year given the 3.3 percent revenue miss for the third quarter and uncertainty surrounding around a large number of binary orders in the fourth quarter. This, according to the firm, is the lowest growth rate since the second quarter of 2012. The company had guided fourth-quarter revenues to be flat to up sequentially.
Challenges
Barclays feels Illumina will be challenged in continuing to push the Next-Generation Sequencing portfolio into clinical markets. In these markets, the firm noted that established reimbursement is weak.
Sagging Product Cycle
While noting that the company's last major product cycle was in 2014, Barclays said it expects the markets to focus on what Illumina can announce in January to accelerate top line growth.
Lowering Price Target, Estimates
Accordingly, Barclays lowered its forecasts and its price target on the shares of the company to $142 from $150. However, the firm maintained its Equal-Weight rating, weighing the company's market leadership in Next Generation Sequencing against the lack of visibility into the next inflection point in growth.
At time of writing, shares of Illumina were down 24.86 percent at $138.92.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.